LT4801B - Alchaimerio ligos profilaktikai ir sulaikymui skirta kompozicija - Google Patents
Alchaimerio ligos profilaktikai ir sulaikymui skirta kompozicija Download PDFInfo
- Publication number
- LT4801B LT4801B LT1999114A LT99114A LT4801B LT 4801 B LT4801 B LT 4801B LT 1999114 A LT1999114 A LT 1999114A LT 99114 A LT99114 A LT 99114A LT 4801 B LT4801 B LT 4801B
- Authority
- LT
- Lithuania
- Prior art keywords
- apo
- phytosterols
- composition
- disease
- cholesterol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/993,901 US5985936A (en) | 1997-12-18 | 1997-12-18 | Method of preventing and delaying onset of Alzheimer's disease and composition therefor |
Publications (2)
Publication Number | Publication Date |
---|---|
LT99114A LT99114A (lt) | 2001-01-25 |
LT4801B true LT4801B (lt) | 2001-06-25 |
Family
ID=25540052
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LT1999114A LT4801B (lt) | 1997-12-18 | 1999-09-16 | Alchaimerio ligos profilaktikai ir sulaikymui skirta kompozicija |
Country Status (18)
Country | Link |
---|---|
US (1) | US5985936A (fr) |
EP (1) | EP0967982A2 (fr) |
CN (1) | CN1252724A (fr) |
AU (1) | AU1656099A (fr) |
BG (1) | BG103740A (fr) |
BR (1) | BR9807577A (fr) |
CA (1) | CA2281710A1 (fr) |
EE (1) | EE9900354A (fr) |
GE (1) | GEP20022783B (fr) |
HU (1) | HUP0100737A3 (fr) |
LT (1) | LT4801B (fr) |
LV (1) | LV12438B (fr) |
MD (1) | MD1920F2 (fr) |
NO (1) | NO993979L (fr) |
PL (1) | PL335421A1 (fr) |
RU (1) | RU2173151C2 (fr) |
SK (1) | SK112999A3 (fr) |
WO (1) | WO1999032097A2 (fr) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060141036A1 (en) * | 1997-12-12 | 2006-06-29 | Andrx Labs Llc | HMG-CoA reductase inhibitor extended release formulation |
US20020107173A1 (en) * | 1999-11-04 | 2002-08-08 | Lawrence Friedhoff | Method of treating amyloid beta precursor disorders |
EP1225880A2 (fr) * | 1999-11-04 | 2002-07-31 | Andrx Corporation | Methode de traitement de troubles lies au precurseur beta-amyloide |
IL152175A (en) | 2000-04-14 | 2005-08-31 | Mars Inc | Compositions and methods for improving vascular health |
US6982251B2 (en) * | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
US20030013692A1 (en) * | 2001-01-19 | 2003-01-16 | Gullans Steven R. | Methods of treating neurological disorders |
US20030105082A1 (en) * | 2001-12-03 | 2003-06-05 | Murphy Greer Marechal | Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4 |
US20040106124A1 (en) * | 2001-02-12 | 2004-06-03 | Murphy Greer M. | Methods for improving the treatment of major depression by genotyping for the gene for apolipoproteine e4 and for improving the terapeutic response of humans having major depression and carrying the gene for apolipoprotein e4 |
US6399310B1 (en) | 2001-02-12 | 2002-06-04 | Akzo Nobel N.V. | Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4 |
DE10154221A1 (de) * | 2001-11-07 | 2003-05-15 | Max Delbrueck Centrum | Mittel zur Behandlung von Läsionen des Nervensystems |
FR2848452B1 (fr) * | 2002-12-12 | 2007-04-06 | Aventis Pharma Sa | Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer |
JP4589919B2 (ja) | 2003-03-07 | 2010-12-01 | シェーリング コーポレイション | 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用 |
CN1756755A (zh) * | 2003-03-07 | 2006-04-05 | 先灵公司 | 取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途 |
US7235543B2 (en) | 2003-03-07 | 2007-06-26 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
US20080182801A1 (en) | 2003-12-22 | 2008-07-31 | Btg International Limited | Core 2 glcnac-t inhibitors |
GB0329667D0 (en) * | 2003-12-22 | 2004-01-28 | King S College London | Core 2 GlcNAc-T inhibitor |
GB0513881D0 (en) * | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Core 2 GLCNAC-T Inhibitors III |
US20050277129A1 (en) * | 2004-01-22 | 2005-12-15 | Genaissance Pharmaceuticals | APOE genetic markers associated with age of onset of Alzheimer's disease |
US7704955B2 (en) * | 2004-11-24 | 2010-04-27 | Neopro Pain, Inc. | Methods and compositions for modulating conditions in both mammals and plants |
GB0512726D0 (en) * | 2005-06-22 | 2005-07-27 | Btg Int Ltd | Multiple sclerosis therapy and diagnosis |
GB0513883D0 (en) * | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Diagnosis of Atherosclerosis |
GB0513888D0 (en) | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Core 2 GLCNAC-T Inhibitors II |
MX2010009649A (es) * | 2008-03-27 | 2010-12-17 | Evotecv Neurosciences Gmbh | Metodos para tratar trastornos utilizando un antagonista selectivo del subtipo nr2b de nmda. |
WO2010104375A1 (fr) * | 2009-03-12 | 2010-09-16 | N.V. Nutricia | Stigmastérol pour le traitement de la maladie d'alzheimer |
US9011937B2 (en) * | 2010-11-22 | 2015-04-21 | Phoenix Biotechnology, Inc. | Method of treating neurological conditions with extract of Nerium species or Thevetia species |
US10383886B2 (en) | 2010-01-11 | 2019-08-20 | Phoenix Biotechnology, Inc. | Method of treating neurological conditions with oleandrin |
US10307450B2 (en) | 2010-01-11 | 2019-06-04 | Phoenix Biotechnology, Inc. | Method of treating neurological conditions with extract of Nerium species or Thevetia species |
US9376481B2 (en) | 2011-04-26 | 2016-06-28 | The Regents Of The University Of California | Methods of promoting CNS neuronal repair by inhibiting LRP-1 |
CN102813659A (zh) * | 2012-08-21 | 2012-12-12 | 贵阳中医学院 | 20α-二甲胺基- 2α-羟基-3β-惕洛酰胺基-5α-孕甾烷的用途 |
WO2015123617A1 (fr) * | 2014-02-14 | 2015-08-20 | Arizona Board Of Regents For The University Of Arizona | Procédé pour réduire l'expression du gène bcl2 |
US10702567B2 (en) | 2016-09-14 | 2020-07-07 | Phoenix Biotechnology, Inc. | Method and compositions for treating viral infection |
US10596186B2 (en) | 2016-09-14 | 2020-03-24 | Phoenix Biotechnology, Inc. | Method and compositions for treating viral infections |
MX2020002884A (es) | 2017-09-14 | 2020-10-05 | Phoenix Biotechnology Inc | Método y composición neuroprotectora mejorada para tratar afecciones neurológicas. |
US11331291B2 (en) | 2017-09-14 | 2022-05-17 | Phoenix Biotechnology, Inc. | Method of and improved composition for treating triterpene-responsive conditions, diseases or disorders |
US20230263809A1 (en) | 2019-12-24 | 2023-08-24 | Folium Biosciences Europe B.V. | Food supplement for alzheimer |
EP3842039A1 (fr) * | 2019-12-24 | 2021-06-30 | Folium Biosciences Europe B.V. | Complément alimentaire comprenant des cannbinoïdes et des phytostérols pour la maladie d'alzheimer |
US11806359B2 (en) | 2020-03-31 | 2023-11-07 | Phoenix Biotechnology, Inc. | Method and compositions for treating Coronavirus infection |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1203515B (it) * | 1987-02-26 | 1989-02-15 | Indena Spa | Complessi di saponine con fosfolipidi e composizioni farmaceutiche e cosmetiche che li contengono |
AU6274394A (en) * | 1993-02-23 | 1994-09-14 | Pharmakon Usa, Inc. | Therapeutic herbal composition |
US5589182A (en) * | 1993-12-06 | 1996-12-31 | Tashiro; Renki | Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression |
SK284250B6 (sk) * | 1994-09-29 | 2004-12-01 | The University Of British Columbia | Kompozícia znižujúca cholesterol, jej použitie a terapeuticky účinný produkt s jej obsahom |
CN1179903A (zh) * | 1996-10-09 | 1998-04-29 | 李辉 | 营养丝米粉 |
CA2289531C (fr) * | 1997-05-15 | 2009-09-29 | University Of Washington | Composition et procedes de traitement de la maladie d'alzheimer et autres amyloidoses |
-
1997
- 1997-12-18 US US08/993,901 patent/US5985936A/en not_active Expired - Fee Related
-
1998
- 1998-12-18 HU HU0100737A patent/HUP0100737A3/hu unknown
- 1998-12-18 SK SK1129-99A patent/SK112999A3/sk unknown
- 1998-12-18 PL PL98335421A patent/PL335421A1/xx unknown
- 1998-12-18 MD MD99-0262A patent/MD1920F2/ro unknown
- 1998-12-18 GE GEAP19984990A patent/GEP20022783B/en unknown
- 1998-12-18 CN CN98804259A patent/CN1252724A/zh active Pending
- 1998-12-18 EP EP98960959A patent/EP0967982A2/fr not_active Ceased
- 1998-12-18 CA CA002281710A patent/CA2281710A1/fr not_active Abandoned
- 1998-12-18 WO PCT/CA1998/001147 patent/WO1999032097A2/fr not_active Application Discontinuation
- 1998-12-18 EE EEP199900354A patent/EE9900354A/xx unknown
- 1998-12-18 RU RU99120072/14A patent/RU2173151C2/ru not_active IP Right Cessation
- 1998-12-18 AU AU16560/99A patent/AU1656099A/en not_active Abandoned
- 1998-12-18 BR BR9807577-2A patent/BR9807577A/pt not_active IP Right Cessation
-
1999
- 1999-08-18 NO NO993979A patent/NO993979L/no not_active Application Discontinuation
- 1999-09-16 LT LT1999114A patent/LT4801B/lt not_active IP Right Cessation
- 1999-09-17 BG BG103740A patent/BG103740A/xx unknown
- 1999-09-17 LV LVP-99-134A patent/LV12438B/en unknown
Non-Patent Citations (6)
Also Published As
Publication number | Publication date |
---|---|
CA2281710A1 (fr) | 1999-07-01 |
HUP0100737A3 (en) | 2002-07-29 |
NO993979D0 (no) | 1999-08-18 |
BR9807577A (pt) | 2001-08-07 |
WO1999032097A2 (fr) | 1999-07-01 |
BG103740A (en) | 2000-05-31 |
WO1999032097A3 (fr) | 1999-09-02 |
LT99114A (lt) | 2001-01-25 |
NO993979L (no) | 1999-10-13 |
EP0967982A2 (fr) | 2000-01-05 |
EE9900354A (et) | 2000-02-15 |
RU2173151C2 (ru) | 2001-09-10 |
AU1656099A (en) | 1999-07-12 |
GEP20022783B (en) | 2002-09-25 |
US5985936A (en) | 1999-11-16 |
MD1920F2 (ro) | 2002-05-31 |
CN1252724A (zh) | 2000-05-10 |
LV12438A (en) | 2000-03-20 |
PL335421A1 (en) | 2000-04-25 |
HUP0100737A2 (hu) | 2001-09-28 |
LV12438B (en) | 2000-09-20 |
SK112999A3 (en) | 2001-11-06 |
MD990262A (en) | 2000-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LT4801B (lt) | Alchaimerio ligos profilaktikai ir sulaikymui skirta kompozicija | |
Kariv-Inbal et al. | The isoform-specific pathological effects of apoE4 in vivo are prevented by a fish oil (DHA) diet and are modified by cholesterol | |
Troutwine et al. | Apolipoprotein E and Alzheimer's disease | |
Chernick et al. | Peripheral versus central nervous system APOE in Alzheimer’s disease: Interplay across the blood-brain barrier | |
Salem Jr et al. | The benefit of docosahexaenoic acid for the adult brain in aging and dementia | |
Martins et al. | Cholesterol metabolism and transport in the pathogenesis of Alzheimer’s disease | |
Yu et al. | The alteration of autophagy and apoptosis in the hippocampus of rats with natural aging-dependent cognitive deficits | |
Vance et al. | Cholesterol homeostasis in neurons and glial cells | |
Karten et al. | Mechanisms and consequences of impaired lipid trafficking in Niemann–Pick type C1-deficient mammalian cells | |
Stein et al. | Lipid transfer proteins (LTP) and atherosclerosis | |
Maria Giudetti et al. | The role of brain cholesterol and its oxidized products in Alzheimer's disease | |
AU9454098A (en) | Methods for increasing apoe levels for the treatment of neurodegenerative disease | |
Teter | ApoE-dependent plasticity in Alzheimer’s disease | |
Montine et al. | Central nervous system lipoproteins in Alzheimer's disease. | |
JP2004505910A (ja) | アポリポタンパク質e分泌を誘導するための方法 | |
Turri et al. | Emerging role of HDL in brain cholesterol metabolism and neurodegenerative disorders | |
Berbée et al. | Apolipoprotein CI knock-out mice display impaired memory functions | |
Takechi et al. | Chylomicron amyloid-beta in the aetiology of Alzheimer's disease | |
Dragan et al. | Can we change the functionality of HDL cholesterol with nonpharmacological and pharmacological agents? | |
JP2013520444A (ja) | 高コレステロール血症を処置するための薬剤及び機序 | |
Levi et al. | Regulation of hippocampal cholesterol metabolism by apoE and environmental stimulation | |
Blain et al. | Cholesterol homeostasis and the pathophysiology of Alzheimer’s disease | |
Galloway et al. | Synergistic effects of high fat feeding and apolipoprotein E deletion on enterocytic amyloid-beta abundance | |
Xu et al. | Lipid metabolism in Alzheimer's and Parkinson's disease | |
Hone et al. | Fat and lipid metabolism and the involvement of apolipoprotein E in Alzheimer's disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM9A | Lapsed patents |
Effective date: 20021218 |